Tuesday, 07 Apr 2020

PsA/SpA

Datesort ascending Type Title Save
13 Nov 2019 Social RT @EBRheum: #ACR19 Abst#2877: Open Label Extension of a Phase 2 for risankizumab (IL23i) for PsA Effect seems to stick around and favorab…
12 Nov 2019 Social RT @philipcrobinson: Video from @gensler_MD on AS and nr-axSpA studies presented at #ACR19 @rheumnow https://t.co/fcn9zCxouU via @YouTube
12 Nov 2019 Social RT @philipcrobinson: Pregnancy outcome in the DESIR cohort (SpA cohort) #ACR19 @RheumNow https://t.co/PcwR6rrMRw
12 Nov 2019 Social RT @DrPetryna: #ACR19 @rheumnow L20 head-to-head IXE vs ADA PSA 52wk trial: IXE shows significantly ⬆️ response than ADA for simultaneous…
12 Nov 2019 Social RT @hausmannMD: Ixekizumab is a high-affinity monoclonal antibody against interleukin-17A. In patients with psoriatic arthritis, ixekizuma…
12 Nov 2019 Social RT @psufka: Abstr# 2440: Strong association between psoriatic arthritis and osteoporosis (45%) and osteopenia (13%). A good reminder to scr…
12 Nov 2019 Social RT @synovialjoints: 5-year effectiveness of TNFi in patients with early axSpA shown, male gender, HLAB27 positive and presence of at least…
12 Nov 2019 Social RT @DrPetryna: @RheumNow #ACR19 #acrbest abs2470 ⬆️serum calprotectin in PsA pts associated w/presence of carotid plaque, ⬆️intima-media th…
12 Nov 2019 Social RT @DrPetryna: @rheumnow #ACR19 abs2854 internationPsART cohort data: age of onset defines if PSO or PSA starts first (PSO precedes in you…
12 Nov 2019 Social RT @uptoTate: The updated ACR/NPF treatment recommendations for PsA were discussed by Dr. Mease and Dr. E. Husni at #ACR19. Will you start…
12 Nov 2019 Social RT @uptoTate: Dr. Mease discusses the ACR/NPF recommendations for treatment naive PsA pts. This slide details starting with TNFi for patien…
12 Nov 2019 Social RT @DrPetryna: @RheumNow #ACR19 abs2467 multicenter observational study analysis concludes sleep impairment in PsA is mainly mediated by su…
12 Nov 2019 Social RT @uptoTate: COAST-X: IXE met ASAS 40 and all secondary endpoints in nr-axSpA vs PBO. https://t.co/V0QNfi33eA #ACR19 @RheumNow plenary#272…
12 Nov 2019 Social RT @EBRheum: #ACR19 Abst#2729 Plenary: Ixekizumab in NR-axSpA Improved ASAS40 at wk16 (32% vs 12% PLBO, NNT~4). Wk52 open label f/u availa…
12 Nov 2019 Social RT @_connectedcare: Ixekizumab in nrAXSpa Outcomes met. Another positive trial #ACR19 @rheumnow Abst2729 https://t.co/VVUKSi6sCQ
12 Nov 2019 Social RT @_connectedcare: Ixekizumab in nrAXSpa: COAST-X switch at wk16 for 52wk study IXE 2wkly vs 4wkly vs PBO 303pts #ACR19 @rheumnow Abst2729
12 Nov 2019 Social Dr Atul Deodhar wows the crowd at #ACR19 showing abtract #2729 Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Phase 3 Trial showing IXE is effective by ASAS40. https://t.co/Bcb20FYNoH
12 Nov 2019 Social RT @EBRheum: #ACR19 Abst#2728 Plenary: Upadacitinib RCT in AnkSpa Improved ASAS40 at wk14 (52% v 26% PLBO, NNT~4) and SPARCC MRI Scores.…
12 Nov 2019 Social RT @_connectedcare: Upadacitinib in AS Nice to the rapid response #ACR19 @rheumnow Abst2728 https://t.co/woAZbdb5QY
12 Nov 2019 Social RT @_connectedcare: Upadacitinib in AS And here’s the Safety Slide #ACR19 @rheumnow Abst2728 https://t.co/fpjhrjGp0N